# Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

> **NCT04338061** · PHASE3 · TERMINATED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 1166 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Teriflunomide
- **DRUG:** Evobrutinib

## Key facts

- **NCT ID:** NCT04338061
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-02
- **Primary completion:** 2023-10-02
- **Final completion:** 2024-03-19
- **Target enrollment:** 1166 (ACTUAL)
- **Why stopped:** Primary analysis of the RMS phase 3 study (MS200527\_0082) resulted in the early termination of the study.
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04338061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04338061, "Study of Evobrutinib in Participants With RMS (evolutionRMS 2)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04338061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*